wp0c6f5671.png
wpeb3c8c0b.jpg

© Climb Mount Kilimanjaro. All rights reserved worldwide

wp7103491c.gif
wp544513bb.gif
wp302f6f39.gif
wp28cc47c5.gif
wp5695802f.jpg
wp5533b116.gif
wpf7a5ce57.jpg
wp5533b116.gif
wp8a76fa24.jpg

Book updates

wpd34cd7c4.png









New study on Kilimanjaro looks at effects of altitude on trekkers
November 30th 2007.

A new study looking into the causes and effects of altitude sickness, or AMS, is due to be launched on Kilimanjaro.

The study will take the form of questionnaires handed out to trekkers and filled out by them on a daily basis as they climb the mountain.

The researchers state that the questionnaire should not take more than 30 seconds to complete each day – presumably in recognition of the fact that knackered Kilimanjaro trekkers are unlikely to want to spend too long on filling out a questionnaire each day, having spent the best part of it walking themselves into a state of exhaustion on the slopes of Kilimanjaro.

The questions themselves divide into several section. The first section looks at the background of each trekker – their height, weight, age, sex, fitness level, whether they have any medical conditions and whether they are taking medication (whether some form of anti altitude sickness drug, such as diamox, or any other form of medication). This section, of course, needs to be filled out only once.

The next section, however, will look at the altitude sickness symptoms each person suffers (or, of course, doesn’t suffer) day by day on the mountain. The questions here will be based on the Lake Louise Mountain Sickness Scoring System, which without getting too scientific is an assessment of five graded symptoms: headache, gi symptoms, fatigue/weakness, dizziness/lightheadedness, and difficulty sleeping. Each trekker roped in to filling out one of these forms will record his symptoms every day, taking note of where and when they got them.

In this way, the researchers hope, they can build up a reasonably accurate picture of exactly who is more likely to suffer from AMS, where and when they are most likely to suffer from it, and how bad the symptoms will be.

I think you’ll agree the results of this study will be fascinating for everybody who has anything to do with the mountain, from the National Park Authorities to the trekking agencies to the trekkers themselves.

We’ll let you know when we hear if and when the study starts, and what, eventually, the results of it are. And if you do happen to be climbing Kilimanjaro in the next twelve months and are asked to take part, do help out if you can – your work will go towards a fascinating piece of research.

 

News October 2007 >>